This study evaluated micro-RNAs expression and outcome in two different cohorts of metastatic colorectal cancer patients treated with cetuximab or panitumumab. High intensity levels of the signature MiR-99a/Let-7c/miR-125b associated with significant longer progression-free survival and overall survival in the whole population and in KRAS wild-type patients. MiR-99a/Let-7c/miR-125b signature may improve the selection of KRAS wild-type patients for anti-EGFR therapy. Background: To investigate whether microRNAs are predictive of sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in patients with metastatic colorectal cancer (mCRC). Methods: A total of 183 mCRC cases from 2 independent cohorts (cohort 1: 74 cases; validation cohort: 109 cases) treated with cetuximab or panitumumab were included in the study. MiRNA arrays were analyzed using Agilent's miRNA platform. Results: The study identified the cluster Let-7c/miR-99a/miR-125b as a signature associated with an outcome different from that of anti-EGFR therapies. In the first cohort, patients with high-intensity signatures had a significantly longer progression-free survival (PFS) (6.1 vs. 2.3 mo; P=.02) and longer overall survival (OS) (29.8 vs. 7.0 mo, P=.08) than patients with low-intensity signatures. In the validation cohort, patients with high signature had significantly longer PFS and OS than individuals with low-intensity signatures (PFS 7.8 vs. 4.3 mo, P=.02; OS 12.8 vs. 7.5 mo, P=.02). In the KRAS wild-type population (n = 120), high-intensity signature patients had a significantly longer PFS (7.8 vs. 4.6 mo, P=.016) and longer OS (16.1 vs. 10.9 mo, P=.09) than low-signature individuals, with no difference in KRAS mutated patients. Conclusion: The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy. (C) 2014 Elsevier Inc. All rights reserved.
MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
CRINO', Lucio;
2014
Abstract
This study evaluated micro-RNAs expression and outcome in two different cohorts of metastatic colorectal cancer patients treated with cetuximab or panitumumab. High intensity levels of the signature MiR-99a/Let-7c/miR-125b associated with significant longer progression-free survival and overall survival in the whole population and in KRAS wild-type patients. MiR-99a/Let-7c/miR-125b signature may improve the selection of KRAS wild-type patients for anti-EGFR therapy. Background: To investigate whether microRNAs are predictive of sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in patients with metastatic colorectal cancer (mCRC). Methods: A total of 183 mCRC cases from 2 independent cohorts (cohort 1: 74 cases; validation cohort: 109 cases) treated with cetuximab or panitumumab were included in the study. MiRNA arrays were analyzed using Agilent's miRNA platform. Results: The study identified the cluster Let-7c/miR-99a/miR-125b as a signature associated with an outcome different from that of anti-EGFR therapies. In the first cohort, patients with high-intensity signatures had a significantly longer progression-free survival (PFS) (6.1 vs. 2.3 mo; P=.02) and longer overall survival (OS) (29.8 vs. 7.0 mo, P=.08) than patients with low-intensity signatures. In the validation cohort, patients with high signature had significantly longer PFS and OS than individuals with low-intensity signatures (PFS 7.8 vs. 4.3 mo, P=.02; OS 12.8 vs. 7.5 mo, P=.02). In the KRAS wild-type population (n = 120), high-intensity signature patients had a significantly longer PFS (7.8 vs. 4.6 mo, P=.016) and longer OS (16.1 vs. 10.9 mo, P=.09) than low-signature individuals, with no difference in KRAS mutated patients. Conclusion: The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy. (C) 2014 Elsevier Inc. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
